

10 July 2025

FY25 Guidance Update

Mach7 Technologies Limited (“M7T” or “the Company”) (ASX:M7T) today provides an update in relation to its expected FY25 results based on preliminary unaudited management accounts.

PRELIMINARY UNAUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2025

- Revenue is expected to finalise at approximately A\$33M-\$34M in line with FY25 guidance for revenue growth of 15-25% (A\$33M-\$36M). This reflected strong growth in recurring revenue¹ of approximately 20%.
- CARR² is expected to finalise at approximately A\$30M-\$31M, slightly below FY25 guidance for CARR growth of 15-25% (A\$32M-\$35M).
- OPEX growth will be less than revenue growth in line with FY25 guidance.

Mach7 is in a strong financial position with no debt and expects to be operating cash flow positive for FY25.

During H2 FY25, Mach7 commenced an on-market share buyback that has acquired approximately 6.3m shares at a cost of A\$2.2M.

The Company expects to have closing cash of approximately A\$21M-\$23M at 30 June 2025.

Mach7 will release its Q4 FY25 result on Tuesday 29 July 2025. An investor webinar with new CEO Teri Thomas and CFO Dyan O’Herne will be held at 9.30am (AEST).

Please refer to the Notice of Result Date announcement for further information.

Released on authority of the Board.

For more information, contact:

Investor Relations
Françoise Dixon
+61 (0) 412 292 977
ir@mach7t.com

About Mach7 Technologies:

Mach7 Technologies (ASX:M7T) is a leading provider of medical imaging software, delivering advanced data management and diagnostic viewing solutions to healthcare organizations worldwide. The Mach7 Enterprise Imaging Solution (EIS) is a next-generation solution combining a powerful Vendor Neutral Archive (VNA), the eUnity Enterprise Diagnostic Viewer, and robust diagnostic workflow applications. Built for maximum flexibility

¹ Recurring revenue consists of Subscription revenue and Maintenance and Support revenue recognised in FY25.

² Contracted Annual Recurring Revenue (CARR)

and scalability, Mach7 empowers customers to implement a complete enterprise imaging ecosystem or deploy modular components that fit their unique needs. Today, Mach7 supports a diverse global network, from large integrated delivery networks (IDNs) and national health systems to independent provider groups and private radiology practices. Visit Mach7t.com for more information.

Forward-looking statements

This announcement may contain forward-looking statements regarding the Company's financial position, business strategy and objectives (rather than being based on historical or current facts). Any forward-looking statements are based on the current beliefs of the Company's management as well as assumptions made by, and information currently available to, the Company's management. Forward-looking statements are inherently uncertain and must be read accordingly. There can be no assurance that some or all of the underlying assumptions will prove to be valid.

All data presented in this announcement reflects the current views of the Company with respect to future events. Forward-looking statements are subject to risk, uncertainties and assumptions relating to the operations, results of operations, growth strategy and liquidity of the Company. To the maximum extent permitted by law, the Company, its officers, employees and agents do not accept any obligation to release any updates or revisions to the information (including any forward-looking statements) in this announcement to reflect any change to expectations or assumptions; and disclaim all responsibility and liability for any loss arising from reliance on this announcement or its contents.



Mach7 Technologies Limited (ASX:M7T) ABN: 26 007 817 192
Registered Office: Suite 2, Level 11, 385 Bourke St, Melbourne, VIC 3000
T: 03 9692 7222
www.mach7t.com